Resources

Youth Ownership of Digital Health (YO.DH) is a volunteer-led community for digital health professionals aged 35 and under, created to build leadership capacity, foster peer networks, and create a platform for knowledge exchange. The initiative rests on three key pillars: community engagement, capacity-building, and networking, aimed at nurturing young, well-informed, and responsible digital health leaders.YO.DH was launched in July 2023, with support from the Gates Foundation, and in partnership with International Innovation Corps, Digital Square, and WomenLift Health. Since then, YO.DH has grown into a thriving, self-sustaining community of over 1,000 members, representing 44 countries and 170 cities.The community prides itself on its gender-inclusive approach, with women constituting 51% of its membership. Members hail from diverse sectors, including civil society organizations, consulting firms, start-ups, non-profits, and government bodies. The community operates based on the principles of Communities of Practice, fostering collaboration, shared learning, and ownership among its members. Its democratic structure ensures broad participation and leadership development, facilitated by a Secretariat, a 19-member core committee comprising members from India and Africa, and rolling cohorts of ambassadors or volunteers serving as champions for youth engagement in digital health.YO.DH reflects a bold shift toward decentralized, peer-driven leadership that values equity, collaboration, and shared ownership. Looking ahead, YO.DH envisions itself as the go-to global platform for young digital health professionals—connecting, creating, and collaborating across borders.Find out more about the project here: https://www.yodh.info/

Effective cold chain equipment (CCE) is the backbone of successful vaccine delivery, but its seamless operation relies on a complex web of “behind-the-scenes” activities. This graphic, produced in collaboration between PATH, JSI, and Village Reach, highlights several crucial activities that are currently being implemented to contribute to robust CCE maintenance systems in multiple countries, such as Nigeria, Kenya, Ethiopia, and Tanzania. While not exhaustive, the activities presented here aim to inspire and inform other countries as we collectively strive to strengthen CCE maintenance globally, ultimately ensuring that lifesaving vaccines reach every person in need.

Regional manufacturing for timely, affordable, and quality-assured diagnostics across the continentAfrica carries nearly a quarter of the global disease burden yet, remains overwhelmingly dependent on imports for essential health products. Today, 95 percent of active pharmaceutical ingredients, 70 percent of medicines, and almost all diagnostics are sourced outside the continent. This dependency drives up costs, slows access, and leaves countries at risk of global supply chain disruptions. The COVID-19 pandemic revealed the weaknesses in Africa’s health supply chains.The gap is especially acute in diagnostics. Despite Africa accounting for the highest burden of diseases such as malaria, tuberculosis, and HIV, most diagnostic tools used to detect these conditions are produced elsewhere. Limited regional manufacturing undermines timely access and constrains Africa’s ability to control and ultimately eliminate these diseases.PATH, supported by Unitaid and a coalition of African and global partners, has launched the Manufacturing to Accelerate Diagnostic Excellence (MADE) in Africa project to address this imbalance. Over the next four years, MADE will work to strengthen and expand Africa’s diagnostic manufacturing ecosystem by:Providing technical expertise to align production with international quality standards.Developing analyses and strategies for climate friendly diagnostics production.Increasing access to financing and investment for African manufacturers.Supporting an existing R&D ecosystem in Africa for diagnostics that will thrive long after the MADE project ends.Driving market-shaping strategies to secure sustainable demand and scale production.By embedding high-quality, affordable diagnostics into regional supply chains, MADE will help meet everyday health needs, strengthen health systems, and build a resilient manufacturing base that can rapidly pivot to produce critical tools during future health emergencies.Ultimately, MADE is about ensuring Africa can rely on its own innovation and capacity to protect the health of its people, independently, affordably, and sustainably.

The malaria parasite develops both in humans and in the female Anopheles mosquitoes. The size and genetic complexity of the parasite mean that each infection presents thousands of antigens (proteins) to the human immune system. The parasite changes through several life stages even while in the human host, presenting different antigens at different stages of its life cycle. Malaria vaccines have the potential to disrupt this life cycle at various stages. The currently available malaria vaccines are pre-erythrocytic vaccines and target the liver stage. Transmission-blocking and blood-stage vaccine candidates are currently under development.This one-page infographic provides an illustration of the malaria parasite life cycle, alongside a step-by-step narrative explaining each stage and where the different types of malaria vaccines target the life cycle. A separate, high-resolution image file of the illustration alone is also available to download.This malaria life cycle graphic may be freely used and copied for educational and other noncommercial purposes, provided that any reproduction is accompanied by the following acknowledgment line: "Reproduced from PATH's website at www.path.org, 2025."

The project ‘Accelerating access and uptake of HIV self-testing (HIVST) in India’ was launched in February 2020 to demonstrate the feasibility and acceptability of HIVST among different key populations (KPs) and other high-risk groups. The overall goal was to increase the demand for and access to HIVST, as well as subsequent treatment and prevention services, thereby contributing to further reduction in the number of new HIV infections and averting deaths due to HIV infection. This report details the approach, methodology, findings, and recommendations from the study.